Literature DB >> 31872382

Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells.

Siqi Xu1, Xiaoyan Wu1, Zhihua Tao2, Hongsheng Li1, Chenliang Fan1, Songjin Chen1, Jianwei Guo1, Yao Ning1, Xuqi Hu3.   

Abstract

BACKGROUND: Androgen-independent prostate cancer (AIPC) is an extremely malignant tumor developed from the androgen dependent (ADPC). However, the mechanism of transition process from ADPC to AIPC remains unknown.
OBJECTIVE: Here we aimed to identify the androgen receptor (AR) target gene and its roles in AIPC.
METHODS: Target genes of AR were identified by ChIP-seq in AIPC cells. AR target gene PCDH7 was detected by real time PCR and western blot. Methylation of PCDH7 was measured by bisulfite sequencing and bisulfite amplicon sequencing. Cell growth, invasion and apoptosis were measured by CCK-8, transwell and flow cytometry, respectively.
RESULTS: AR was significantly enriched in the upstream of PCDH7 gene. The expression of PCDH7 was significantly decreased, while the methylation of PCDH7 was increased in the AIPC cells compared to the ADPC cells. DNA methyltransferase inhibitor significantly suppressed the methylation and increased the mRNA and protein level of PCDH7. Moreover, overexpression of DNMT1 remarkably reduced the mRNA and protein level of PCDH7. DNA methyltransferase inhibitor decreased the cell growth and invasion while promote the cell apoptosis in the AIPC cells. AR significantly target PCDH7, whose hypermethylation may repress cell growth and invasion, and promote apoptosis in AIPC.
CONCLUSIONS: This study might provide a novel potential target for the treatment of AIPC.

Entities:  

Keywords:  Androgen; Methylation; PCDH7; Prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31872382     DOI: 10.1007/s13258-019-00903-w

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  28 in total

Review 1.  Androgen action in the prostate gland.

Authors:  N Yadav; H V Heemers
Journal:  Minerva Urol Nefrol       Date:  2012-03       Impact factor: 3.720

2.  Androgen deprivation therapy for prostate cancer.

Authors:  Robert Bahnson
Journal:  J Urol       Date:  2007-08-14       Impact factor: 7.450

3.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

Authors:  Guillermo Garcia-Manero; Hagop M Kantarjian; Blanca Sanchez-Gonzalez; Hui Yang; Gary Rosner; Srdan Verstovsek; Michael Rytting; William G Wierda; Farhad Ravandi; Charles Koller; Lianchun Xiao; Stefan Faderl; Zeev Estrov; Jorge Cortes; Susan O'brien; Elihu Estey; Carlos Bueso-Ramos; Jackie Fiorentino; Elias Jabbour; Jean-Pierre Issa
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

4.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

Authors:  C W Gregory; B He; R T Johnson; O H Ford; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

5.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

Review 6.  Androgen receptor in prostate cancer.

Authors:  Cynthia A Heinlein; Chawnshang Chang
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

Review 7.  Androgen deprivation therapy for prostate cancer.

Authors:  Eric A Singer; Dragan J Golijanin; Hiroshi Miyamoto; Edward M Messing
Journal:  Expert Opin Pharmacother       Date:  2008-02       Impact factor: 3.889

8.  Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer.

Authors:  M Dror Michaelson; Rose M Marujo; Matthew R Smith
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.

Authors:  Ying-Li Lin; Yan-Ling Wang; Xing-Li Fu; Wen-Ping Li; Yu-Hao Wang; Jian-Guo Ma
Journal:  Oncotarget       Date:  2016-05-10
View more
  1 in total

1.  The predictive prognostic values of CBFA2T3, STX3, DENR, EGLN1, FUT4, and PCDH7 in lung cancer.

Authors:  Yuhao Chen; Lu Shen; Bairong Chen; Xiao Han; Yunchi Yu; Xiaosa Yuan; Lou Zhong
Journal:  Ann Transl Med       Date:  2021-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.